Abstract | PURPOSE: METHODS: Managed care enrollees newly prescribed celecoxib, rofecoxib, ibuprofen, naproxen or diclofenac were identified. Time to switch to a different NS- NSAID or COX-2 specific inhibitor was determined using time-to-event analysis and Cox proportional hazards models were used to estimate the odds ratio (OR) after controlling for potential confounders. RESULTS: The time to 25% of the cohort switching was longer for rofecoxib and celecoxib (159 and 205 days respectively) compared to the three NS- NSAIDs (49-78 days). Patients were at the highest risk of switching within the first 100 days of therapy. After adjusting for potential confounding factors, the OR for switching to another NS- NSAID or COX-2 specific inhibitor ranged from 1.74 to 2.35 for the three NS- NSAIDs compared to celecoxib (all comparisons, p < 0.01). Similar findings were obtained when comparing rofecoxib to each of the three NS- NSAIDS (all comparisons, p < 0.01). When COX-2 inhibitors combined were compared to NS- NSAIDS combined, the OR for switching was 1.53 (95% confidence interval = 1.42-1.65; p < 0.01) after adjusting for potential confounders. CONCLUSIONS: Patients on the COX-2 specific inhibitors ( celecoxib and rofecoxib) were significantly less likely to switch their therapy than patients on NS- NSAIDS ( ibuprofen, naproxen and diclofenac). These results suggest that COX-2 specific inhibitors may be a more effective treatment option when compared with NS- NSAIDs in usual clinical practice.
|
Authors | Sean Z Zhao, Chuck Wentworth, Thomas A Burke, Robert W Makuch |
Journal | Pharmacoepidemiology and drug safety
(Pharmacoepidemiol Drug Saf)
Vol. 13
Issue 5
Pg. 277-87
(May 2004)
ISSN: 1053-8569 [Print] England |
PMID | 15133778
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2003 John Wiley & Sons, Ltd. |
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Cyclooxygenase Inhibitors
- Lactones
- Pyrazoles
- Sulfonamides
- Sulfones
- rofecoxib
- Celecoxib
|
Topics |
- Adult
- Anti-Inflammatory Agents, Non-Steroidal
(administration & dosage, therapeutic use)
- Arthritis, Rheumatoid
(complications, drug therapy)
- Celecoxib
- Cyclooxygenase Inhibitors
(administration & dosage, therapeutic use)
- Female
- Gastrointestinal Diseases
(complications)
- Humans
- Lactones
(administration & dosage, therapeutic use)
- Male
- Middle Aged
- Osteoarthritis
(complications, drug therapy)
- Pharmacoepidemiology
- Proportional Hazards Models
- Pyrazoles
- Sulfonamides
(administration & dosage, therapeutic use)
- Sulfones
- Time Factors
|